Biotech Values

[DewDiligence]

ANNX IPOs 16.96M* shares @17.00:

https://www.globenewswire.com/news-release/2020/07/24/2067083/0/en/Annexon-Announces-Pricing-of-Initial-Public-Offering.html

Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye.

…The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders.

*Assuming exercise of underwriter’s option.